Identification of ubiquitination-related genes in human glioma as indicators of patient prognosis

PLoS One. 2021 Apr 29;16(4):e0250239. doi: 10.1371/journal.pone.0250239. eCollection 2021.

Abstract

Ubiquitination is a dynamic and reversible process of a specific modification of target proteins catalyzed by a series of ubiquitination enzymes. Because of the extensive range of substrates, ubiquitination plays a crucial role in the localization, metabolism, regulation, and degradation of proteins. Although the treatment of glioma has been improved, the survival rate of patients is still not satisfactory. Therefore, we explore the role of ubiquitin proteasome in glioma. Survival-related ubiquitination related genes (URGs) were obtained through analysis of the Genotype-Tissue Expression (GTEx) and the Cancer Genome Atlas (TCGA). Cox analysis was performed to construct risk model. The accuracy of risk model is verified by survival, Receiver operating characteristic (ROC) and Cox analysis. We obtained 36 differentially expressed URGs and found that 25 URGs were related to patient prognosis. We used the 25 URGs to construct a model containing 8 URGs to predict glioma patient risk by Cox analysis. ROC showed that the accuracy rate of this model is 85.3%. Cox analysis found that this model can be used as an independent prognostic factor. We also found that this model is related to molecular typing markers. Patients in the high-risk group were enriched in multiple tumor-related signaling pathways. In addition, we predicted TFs that may regulate the risk model URGs and found that the risk model is related to B cells, CD4 T cells, and neutrophils.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Brain Neoplasms / genetics
  • Databases, Genetic
  • Gene Expression Profiling / methods
  • Gene Expression Regulation, Neoplastic / genetics
  • Glioma / genetics*
  • Glioma / metabolism
  • Glioma / physiopathology
  • Humans
  • Prognosis
  • ROC Curve
  • Risk Factors
  • Survival Rate
  • Transcriptome
  • Ubiquitination / genetics*

Substances

  • Biomarkers, Tumor

Grants and funding

The present study was supported by the National Natural Science Foundation of China (81874081, 81672490), the Foundation of Jiangsu Provincial Health Department (grant no. YG201514), the Foundation of Xuzhou Medical University (grant no. 2018KJ09) and Xuzhou Science and Technology Plan Project (grant no. KC20139). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.